Assessing Impact of Health System Specialty Pharmacy Support on Initiation of Vigabatrin Therapy for Infantile Epileptic Spasms Syndrome

Clicks: 13
ID: 329627
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #229 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose Infantile epileptic spasms syndrome (IESS) is a severe form of pediatric epilepsy requiring urgent diagnosis and treatment. Vigabatrin is a standard therapy but often requires inpatient initiation because of delays in outpatient access due to prior authorization (PA) requirements and distribution restrictions. The primary objective was to determine if a proactive vigabatrin PA workflow through health system specialty pharmacy (HSSP) reduced hospital admission for treatment initiation. This study also explored the time from vigabatrin initiation to PA approval and the number of patients starting vigabatrin within 14 days of prior treatment. Methods This retrospective, single-center study evaluated patients aged one month to two years with new-onset IESS and treated with vigabatrin. Patients treated between May 1, 2019, and December 31, 2024, were compared with those treated between March 1, 2025, and December 31, 2025. Demographic, clinical, and medication access data were analyzed using descriptive and comparative statistics. Results Each cohort contained 19 patients with similar baseline characteristics. Hospital admissions for vigabatrin initiation decreased from 57.9% to 5.3% (p < 0.001). In the pre-intervention cohort, PA approval occurred on the day of vigabatrin initiation, whereas in the post-intervention cohort approval occurred a median of 5 days before initiation (p = 0.04). The number of patients starting vigabatrin within 14 days of first treatment was similar between cohorts (12 and 13 respectively, p = 0.73). Conclusions Implementation of a HSSP-driven proactive PA workflow significantly reduced hospital admissions for vigabatrin initiation and permitted earlier PA approval supporting HSSP integration for time-sensitive therapies.
Reference Key
openalex_W7214215867 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jillian Gould, Kayla Petkus, John R. Mytinger, Dana M Wilkerson, Becky Nugent, Taylor M Duque
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag304
URL
https://doi.org/10.1093/ajhp/zxag304
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.